Opinion

Video

Tailoring CDK4/6 Inhibitor Treatment to Patient Needs

A leading breast cancer specialist examines the growing role of CDK4/6 inhibitors in the adjuvant treatment of HR+/HER2- early breast cancer, citing the monarchE and NATALEE trials, and explores patient and disease-related factors that guide the decision to incorporate CDK4/6 inhibitors in this context.

  1. In the adjuvant treatment of HR+/HER2- early breast cancer, endocrine therapy has traditionally played a crucial role, with CDK4/6 inhibitors becoming more prominent in recent years through the monarchE and NATALEE trials. What factors related to the patient or disease influences the decision to utilize a CDK4/6 inhibitor in this setting?
Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
Justin Oldham, MD, MS, an expert on IPF
Mei Wei, MD, an oncologist specializing in breast cancer at Huntsman Cancer Institute at the University of Utah.
Dr Bonnie Qin
Screenshot of an interview with Ruben Mesa, MD
Justin Oldham, MD, MS, an expert on IPF
Ruben Mesa, MD
Amit Garg, MD, Northwell Health
4 KOLs are featured in this series
Related Content
Closeup of hand with cardiogram on red heart | Image Credit: Syda Productions - stock.adobe.com
November 21st 2024

Higher Life’s Essential 8 Scores Associated With Reduced COPD Risk

Brooke McCormick
Higher Life’s Essential 8 (LE8) scores, especially those reflecting lower nicotine exposure and better sleep health, are inversely associated with chronic obstructive pulmonary disease (COPD) risk, emphasizing the importance of cardiovascular health (CVH) in disease prevention.
Managed Care Cast
October 29th 2024

Breaking the Cycle: The Importance of Early Intervention in Hidradenitis Suppurativa

Giuliana Grossi
Prompt care supports mental well-being, as hidradenitis suppurativa is often associated with depression and anxiety due to its physical and social challenges.
Patient in the hospital - Tyler Olson -stock.adobe.com.jpg
November 20th 2024

New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease

Giuliana Grossi
Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Managed Care Cast logo
July 18th 2024

Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value

Brooke McCormick
On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Multiple Myeloma | Image Credit: © Dzmitry-stock.adobe.com
November 19th 2024

OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM

Jordyn Sava
The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Oseltamivir being prescribed to patient | Image Credit: cristianstorto - stock.adobe.com
November 19th 2024

Influenza Antiviral Treatment Underutilized Among Eligible Children, Adolescents

Brooke McCormick
Influenza antiviral treatment remains underutilized among eligible children and adolescents, particularly in outpatient settings, despite CDC recommendations.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo